Publication:

Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation

Loading...
Thumbnail Image

Open/View Files

Date

2015

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Nature Pub. Group
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Papaspyridonos, M., I. Matei, Y. Huang, M. do Rosario Andre, H. Brazier-Mitouart, J. C. Waite, A. S. Chan, et al. 2015. “Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation.” Nature Communications 6 (1): 6840. doi:10.1038/ncomms7840. http://dx.doi.org/10.1038/ncomms7840.

Abstract

A central mechanism of tumour progression and metastasis involves the generation of an immunosuppressive ‘macroenvironment' mediated in part through tumour-secreted factors. Here we demonstrate that upregulation of the Inhibitor of Differentiation 1 (Id1), in response to tumour-derived factors, such as TGFβ, is responsible for the switch from dendritic cell (DC) differentiation to myeloid-derived suppressor cell expansion during tumour progression. Genetic inactivation of Id1 largely corrects the myeloid imbalance, whereas Id1 overexpression in the absence of tumour-derived factors re-creates it. Id1 overexpression leads to systemic immunosuppression by downregulation of key molecules involved in DC differentiation and suppression of CD8 T-cell proliferation, thus promoting primary tumour growth and metastatic progression. Furthermore, advanced melanoma patients have increased plasma TGFβ levels and express higher levels of ID1 in myeloid peripheral blood cells. This study reveals a critical role for Id1 in suppressing the anti-tumour immune response during tumour progression and metastasis.

Description

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories